REPI : a Randomized Open Label Trial Evaluating the Use of APC in Pre-Implantation Reconstruction of Maxilla
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a randomized open label trial that evaluates the efficacy of an autologous platelet concentrate (APC) in pre-implantation reconstruction of maxilla.
The sinus occlusion will be performed under general anaesthetic. On one side by the usual technique with hipbone transplant, the other side will be restored with APC mixed with autologous bone tissue removed from the surgery site.
The side selection will be determined by the randomization.
| Condition | Intervention | Phase |
|---|---|---|
|
Jaw, Edentulous Tooth Loss Maxillary Diseases |
Procedure: cellular therapy : Autologous platelet concentrate (APC) |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Use of Autologous Platelet Concentrate in Pre-Implantation Reconstruction of Maxilla. |
- Radiological outcome measure : the bone height under the sinus on the two sides.
- Radiological outcome measure : the bone density
- Clinical outcome measure : assessment of the alveolar crest quality, possible orals complications, and complications at the removal site.
- Histological outcome measures : with bone core boring at the implant site.
- All these measurements will be matched for each patient on both sides.
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2003 |
| Study Completion Date: | November 2007 |
Rational
Maxillary Edentulous is one of the more frequent handicaps that cause many problems for dental prosthesis. Dental implants are currently the most convenient solution but require sufficient bone sinus height.
The filling of the sinus can be made by two ways :
- Either with autologous bone removed from hipbone or cranial bone. This method has several drawbacks such as the multiplicity of the surgery sites.
- Or with alloplasty materials that are subject to uncertain osseointegration and that are very expensive.
The aim of this study is to show the interest of an autologous platelet concentrate (APC) in this surgery. We will use the osteogenic property of platelets associated with a small quantity of spongy bone removed from the surgery site.
It has been previously demonstrated that platelets contain growth factors, in particular PDGF (platelet derivated growth factors), TGF-α1 and 2 (transforming growth factors) and IGF-1 (insulin like growth factor). These molecules have receptors on spongy bone, enhance mitosis, osteoblast differentiation, angiogenesis and induce the inhibition of osteoclats.
Method :
The sinus filling will be performed under general anaesthetic. On one side by the usual technique with hipbone transplant, the other side will be restored with APC mixed with autologous bone tissue removed from the surgery site.
The side selection will be determined by the randomization. For each patient a waiting period of 6 months is required before dental implants.
Twenty patients will be enrolled in this single-centre study with a follow-up of one year.
Main objective :
- To demonstrate that the osteogenesis with APC mixed with a small quantity (1 to 2 cm2) of autologous bone tissue removed from the surgery site, has a sufficient quality to allow the dental implants.
Secondary Objectives :
- To compare the osteogenesis with the current procedure (hipbone transplant)
- To estimate the kinetic of osteogenesis using successive radiography.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age above 18 years
- ASA1 class of anesthetic risk
- SA3 or SA4 of the Misch classification
Exclusion Criteria:
- Smoker
- Progressive sinusal lesion or previous history of maxillary sinusitis
- Previous history of maxillary surgery
- Hemopathy
- Contraindication to cytapheresis
- Progressive cardiopathy
- Severe cerebellar arteriopathy
- Infectious state
- Thrombopenia < 150 g/l controlled by citrate
- Serology : antibody anti-HVC, anti-HIV 1 & 2, anti HTLV 1 & 2 positive
Contacts and Locations| France | |
| University Hospital of Grenoble | |
| Grenoble, Isere, France, 38043 | |
| Principal Investigator: | Georges Bettega, Dr | Univesity Grenoble Hospital, Stomatology Department |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00295126 History of Changes |
| Other Study ID Numbers: | DCIC 01 12 |
| Study First Received: | February 20, 2006 |
| Last Updated: | March 11, 2008 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Grenoble:
|
Edentulous Tooth Loss APC Autologous platelet concentrate |
Additional relevant MeSH terms:
|
Jaw, Edentulous Maxillary Diseases Mouth, Edentulous Tooth Loss Jaw Diseases |
Musculoskeletal Diseases Stomatognathic Diseases Mouth Diseases Tooth Diseases Periodontal Diseases |
ClinicalTrials.gov processed this record on May 21, 2013